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Bone ultrastructure and x-ray microanalysis of aluminum-intoxicated
hemodialyzed patients. In hemodialyzed patients aluminum (Al) intoxi-
cation may induce osteomalacic lesions which are mainly observed
when plasma immunoreactive parathyroid hormone (iPTH) concentra-
tions are low, and osteitis fIbrosa absent. In this study, the bone tissue
of eight hemodialyzed patients with elevated plasma and bone Al
concentrations was examined by histomorphometry, electron micros-
copy, and x-ray microanalysis. Five patients (group 1) had osteomalacia
and minimal osteitis fibrosa, three patients (group 2) had severe osteitis
fibrosa. In group I, Al was concentrated at the mineralizing front, in
hexagonal structures measuring 200 to 1,000 A which also contained
phosphorus, but not calcium. Hydroxyapatite needles had a normal
aspect. Osteoblasts appeared inactive. In group 2, Al was also present
at the mineralizing layer of osteold, but, in these cases, in small clusters
next to abnormal calcium deposits. Osteoblasts appeared very active.
Their mitochondria contained calcium and phosphorus granules, or
amorphous material, measuring 1,500 to 2,000 A, emitting x-rays
characteristic for Al and phosphorus. These results suggest that second-
ary hyperparathyroidisni, by stimulating the cellular activity, may
increase the uptake and release of Al by the osteoblasts. The presence
of Al within the mitochondria of these cells may be one of the factors
inducing the mineralization defect.
Ultrastructure et microanalyse x du tissu osseux de malades hemodia-
lysés intoxiqués par l'aluminium. Chez des malades hemodialysés
l'intoxication par l'aluminium (Al) peut induire des lesions ostéomalaci-
ques qui s'observent principalement quand Ia concentration plasmati-
que de l'hormone parathyroIdienne immunoréactive (iPTH) est peu
augmentée, et en l'absence d'ostéite fibreuse. Dans cette étude le tissu
osseux de huit malades hémodialysés dont Ia concentration plasmatique
et osseuse de l'Al était élevée, a eté examine par l'histomorphométrie,
La microscopic electronique et la microanalyse x. Cinq malades (groupe
I) avaient une ostéomalacie et des lesions minimes d'ostéite fibreuse,
trois malades (groupe 2) avaient une ostéite fibreuse sévCre. Dans le
groupe 1, l'Al était concentré entre ostéoIde et tissu minCralisC, dans
des structures hexagonales mesurant 200 a 1000 A, qui contenaient
egalement du phosphore, mais pas de calcium. Les aiguilles d'hydrox-
yapatite avaient un aspect normal. Les ostéoblastes paraissaient peu
actifs. Dans Ic groupe 2, l'Al était aussi present entre ostéoIde et tissu
minéralisé, mais, dans cc cas, sous forme de petits amas, prés de dépóts
anormaux de calcium. Les ostéoblastes semblaient trés actifs. Leurs
mitochondries contenaient des granules de calcium et de phosphore ou
bien du materiel amorphe, mesurant 1500 a 2000 A, dont l'émission x
était caractéristique de l'Al et du phosphore. Ces résultats suggerent
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que l'hyperparathyroIdie secondaire, en stimulant l'activité cellulaire,
favorise Ia captation et le dépôt de l'Al par les ostéoblastes. La
presence d'Al dans les mitochondries de ces cellules pourrait être un
des facteurs a l'origine du trouble de Ia minéralisation.
In hemodialyzed patients aluminum (Al) intoxication is often
associated with a mineralization defect of the bone matrix. This
association has been demonstrated by epidemiological and
histological studies: High Al dialysate, which is one of the
sources of the intoxication, is related to the incidence of
fracturing bone disease [1], and the Al content of bone is related
to the severity of the osteomalacic lesions [2, 3]. Furthermore,
in the bone tissue of intoxicated patients, we were able to show
that Al is concentrated at the mineralizing layer of osteoid [2,
4]. This same localization has been observed by Boyce Ct al [5]
and Maloney et al [61. In addition, the parenteral administration
of Al to rats induces lesions similar to those observed in
humans, thus providing evidence that Al directly interferes with
bone mineralization [7, 8]. However, the mechanism of this
action is still unknown.
It has been suggested that Al binds to mineral already laid
down and blocks the deposition of normal mineral [6]. Further-
more, there is evidence for a relation between Al intoxication
and the status of the parathyroid glands, since an inverse
correlation has been reported between bone Al and bone
resorbing surfaces, and plasma immunoreactive parathyroid
hormone (iPTH) concentrations [3]. In addition, patients with
Al-induced osteomalacia have relatively low plasma iPTH
levels, and minimal lesions of osteitis fibrosa [2, 3]. However,
in some patients with elevated bone Al concentrations and
severe osteitis fibrosa, bone matrix mineralization may be
normal or only slightly defective [2].
In an attempt to clarify the mechanism of the toxic action of
Al on bone, and the relation between this action and secondary
hyperparathyroidism, the bone tissue of two groups of hemo-
dialyzed patients with elevated plasma Al concentrations was
examined by histomorphometry, ion microscopy, electron mi-
croscopy, and x-ray microanalysis. One group had severe
osteomalacia and minimal lesions of osteitis fibrosa, while the
other one had severe osteitis fibrosa and only minor mineraliza-
tion defect.
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Table 1. Clinical data and plasma biochemistry of the patients studied
Patients
Group 1 Group 2
1 2 3 4 5 6 7 8
Age, years 34 50 54 65 48 57 46 46
Sex M M M M M M F M
Type of nephropathy CGN CGN Polycystic
disease
CPN CGN Familial
nephropathy
CPN —
Duration of dialysis,
years 10 8 8 7 3 6 5 7
OF
Radiology OM
0
+
0
+
(+)
+ +
0
0
0
+
+
0
+++
0
++
0
Clinical
Encephalopathy EEG
0
0
+
+
0
0
+
+
+
÷
0
+
0
—
0
+
Calcium, mmoles/litera 2.6 0.15 2.56 0.19 2.36 0.12 2.42 0.16 2.51 0.15 2.36 0.02 2.72 0.03 2.62 0.22
Phosphorus, mmoles/
liter" 2.38 0.46 2.33 0.35 1.66 0.32 1.46 0.15 1.2 0.21 2.77 0.14 2.12 0.09 1.35 0.16
Alkaline phosphatases,
nkat/liter N N N 2270 (+) 1700 5600 3750
iPTH, ng/ml" 0.15 0.10 0.10 0.8 1.7 1.6 3.6 2.7
Aluminum, pmoles/litero 4.4 (7.4) 3.3 (29.6) 2.8 (8.5) 4.4 (8.1) 9.2 (20.7) 7.4 (14,8) 4 (14.8) 7.4 (22.2)
Abbreviations: CGN, chronic glomerulonephritis; CPN, chronic pyelonephritis; —, unknown;OF, osteitis fibrosa; OF column, (+) and + denote
granular rarefaction of the skull and/or mild erosions of phalanges, + + numerous erosions of phalanges, and + + + partial dissolution of terminal
phalanges and erosions of claviculae; OM, osteomalacia; OM column, + denotes one pathological fracture or Looser zone and + + multiple
pathologic fractures.
a The values represent the mean SD during the 6 months prior to biopsy (N = 2.25 — 2.62 mmoles/liter).
b The values represent the mean SD during the 6 months prior to biopsy (N = 0.81 — 1.45 mmoles/liter).
N < 1500 nKat/liter; (+) denotes 50% increase above normal.
d N  0.5 ng/ml.
Values in parentheses indicate the highest values measured during the months prior to biopsy (N < 0.4 zmoles/liter).
Table 2. Bone aluminum concentration and histomorphometry of the two groups of patients
Patients
Group 1 Group 2 Normal
valuesa1 2 3 4 5 6 7 8
Al, p.moles/g" 3.48 2.48 2.11 1.15 2.11 3.26 2.6 1.41 <0.3
Bone volumec 36 23 24.5 17.7 18 30.2 35.5 45.9 21 4
Osteoid volumed 19.6 18.3 20.6 24 23.8 18.9 11.2 11.7 5 3
Osteoid surfacee 61.5 76 76.3 55 72 75 68.2 65.6 13.9 6.6
Mineralization front 15.8 6.2 3 0 16 58.5 68.4 54.2 63.3 4.5
Mean seam thickness, j.m 26.2 16.4 23 20.4 15 20 12 14 10 3
Osteoblast surfaces 1.8 0 0.3 0 1.3 16.8 34.8 20.7 4.7 3.4
Osteoclast surface" 3.6 0 0.16 1.33 1.3 9.8 9.4 4.4 0.53 0.54
Marrow fibrosis1 0 0 0 0 0.1 3.9 7.2 6.6 0
a Values are means SD, except for aluminum content and marrow fibrosis.
b Al is expressed in grams of wet weight of bone tissue.
The remaining footnotes denote volumes and surfaces in percentages as specified below:
Spongiosa volume composed of mineralized and nonmineralized bone matrix.
d Bone volume occupied by osteoid.
Trabecular surface lined by osteoid tissue.
Osteoid surface exhibiting orthochromatic granules at the limit between calcified and noncalcified matrix on toluidine blue-stained sections.
Trabecular surface lined by active osteoblasts.
Trabecular surface covered by osteoclasts.
i Spongiosa volume occupied by fibrous tissue.
Methods months prior to bone biopsy. Dialysate calcium concentration
was 1.75 nimoles/liter.
Patients. All the patients studied had plasma Al concentra- All subjects had previously received vitamin D metabolites
tions of 7.4 jimoles/liter or more at the time the bone biopsy was (25-hydroxycholecalciferol and/or Ia-hydroxycholecalciferol)
performed or during the months preceding the biopsy. Relevant prior to the bone biopsy. There was no evidence for chronic
clinical and biochemical data are indicated in Table 1. In all calcium or phosphate depletion in any patient. According to
subjects, hemodialysis was performed for 12 to 16 hr weekly. bone histomorphometry (Table 2) two groups of patients were
Softened water was used for dialysate preparation, except for defined: group 1 (patients 1 to 5): subjects with severe osteoma-
patient 8, for whom deionized water was used during the 7 lacia (mineralization front equal or below 16%), and absent or
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minimal lesions of osteitis fibrosa. In this group, one subject
(patient 2) underwent subtotal parathyroidectomy 9 months
prior to the bone biopsy; group 2 (patients 6 to 8): subjects with
severe osteitis fibrosa and normal extent of the mineralization
front. Prior to bone biopsy patient 8 received a single tetracy-
cline label and patients 6 and 7 received double tetracycline
labels.
Data concerning patients 1, 2, 3, 5, and 6 have recently been
reported elsewhere [21.
Plasma Biochemistry. In all patients, blood samples were
obtained immediately before dialysis. Plasma calcium and phos-
phorus were measured by an autoanalyzer (SMA 12-60, Techni-
con, Domont, France) plasma alkaline phosphatase, according
to a kinetic method [9], except for patients 1, 2, 3, and 5. Since
in these patients measurements were performed in different
laboratories with different techniques, the following symbols
were used, for interpretation purposes: N for normal and (+),a
50% increase in plasma alkaline phosphatases activities. Plasma
iPTH was measured by a modification of the method of Arnaud,
Tsao, and Littledike [l0J. The antibody used (chicken antibo-
vine PT!!) predominantly detects the carboxyterminal frag-
ments, and the values are expressed as equivalents of pure
bovine PTH. The lower limit of detection is 0.08 nglml (normal
values: 0.50 nglml) with an intraassay coefficient of variation
of 12% and an interassay coefficient of variation of 20%. The
correlation coefficient between bone histology (osteoclast sur-
face) and iPTH plasma concentration, calculated on the values
obtained in 60 hemodialyzed patients in which biopsy speci-
mens were taken during the past 2 years, was r = 0.66 (P <
0.01) (unpublished results). Al was measured by flameless
atomic absorption using a graphite furnace [ii].
Bone studies. Bone biopsy specimens were obtained from the
anterior iliac crest. From each specimen a small piece of
cortical bone was taken for Al analysis, ito 2 mm thick samples
of trabecular bone were taken for electron microscopy and x-
ray microanalysis, and the remaining part of the biopsy was
prepared for light microscopy. Bone Al was measured by the
same technique as plasma Al.
All samples were fixed in a cacodylate-buffered 2.5% solution
of glutaraldehyde and paraformaldehyde, without the addition
of calcium or magnesium. The water used for histological
processing was controlled deionized water.
Optical microscopy and morphometry. The samples were
embedded in methylmethacrylate without decalcification. Sec-
tions 4-sm thick were cut with a microtome (A. 0. Spencer,
Buffalo, New York), equipped with a knife with tungsten
carbide cutting edge, and stained with toluidine blue. Morpho-
metric data were obtained with an integrating eyepiece (II,
Zeiss, Oberkochen, West Germany) as previously reported [2].
Electron microscopy. Following glutaraldehyde and parafor-
maldehyde fixation, samples of patients 1, 2, 3, 5, and 6 were
postfixed for 2 hr with 1% osmium tetroxyde. Those of patients
4, 7, and 8 were not postfixed, to allow easier identification by
x-ray microanalysis of the Ka line of phosphorus which is close
to the Ma line of osmium (see below and Fig. 3A, inset).
Samples from all patients were rinsed, dehydrated in graded
series of ethanol and embedded in Epon 812. Thin sections (600
to 800 A), obtained with an ultramicrotome (ultratome III,
LKB, Bromma, Sweden) with a diamond knife were spread on
Tris-maleate buffer and mounted on copper or titanium grids.
The sections were examined without staining or were stained
with uranyl-acetate and lead citrate.
Ion microscopy and electron microprobe. For ion microsco-
py, 1-pm semithin sections were mounted on a silver support
and examined by an ion analysis (CAMECA IMS 300, Courbe-
voie, France). The images obtained were compared with the
light microscopic aspect of serial sections stained with aqueous
toluidine blue. More details on this technique have been report-
ed elsewhere [2]. For x-ray microanalysis 600 A thick unstained
sections were mounted on titanium grids, carbon-coated, and
studied by electron microprobe (CAMECA MBX). The acceler-
ating voltage was 45 kV, the beam current intensity 150 or 50
nA, for diameters of the incident electron beam of 0.5 or 0.2
pm, respectively. The Ka lines for Al, phosphorus, and calcium
and the Ma and Mf3 lines for osmium were identified with a
thallium acid phtalate crystal.
Results
Group 1. In the bone tissue of all patients of this group severe
osteomalacia was observed (Table 2), that is, low extent of the
mineralization front and increased mean osteoid seam thick-
ness, osteoid volume, and osteoid surface. Marrow fibrosis was
absent in all patients, except in patient 5, in whom it was
minimal. The number of osteoclasts was low in patients 2 and 3
and slightly elevated in the others. The number of active
osteoblasts was reduced in all patients. In all patients the Al
content of bone was high, and ion microscopy showed that Al
was concentrated at the mineralizing layer of osteoid. Figure 1
A and B shows the distribution of Al in a bone section of patient
1, compared with a serial section stained by toluidine blue: Al
clearly appears between osteoid and calcified tissue. In this
region EM analysis of unstained sections showed that although
the hydroxyapatite needles were disposed in irregular clusters,
the single needles were sharply defined and did not appear
abnormal. No other calcium-containing deposits were ob-
served. In addition, in all patients hexagonal structures were
observed in the same zone, measuring 200 to 1,000 A in
diameter (Fig. 1 C and D). These structures were either free in
the osteold matrix or appeared bound to fine hydroxyapatite
needles. Their x-ray emission was characteristic for Al and
phosphorus (Fig. 1, C inset) and, in those lying free, no calcium
could be detected. Smaller structures, with the same shape,
were also seen inside the incompletely mineralized osteoid. In
this group of patients, the ultrastructural morphology of the
bone cells indicated reduced cellular activity. Cuboidal osteo-
blasts were not observed. The cells lining the bone surfaces
were flattened, fibroblast-like cells showing no cytoplasmic
processes extending into the ostëoid. The endoplasmic reticu-
lum was almost absent and the mitochondria devoid of electron-
dense material. Nor did the osteocytes show evidence of
cellular activity: Their cytoplasm contained few organelles, the
lacunar wail was smooth, and the lacunar cavity contained
flocculent material. No osteoclasts could be visualized.
Group 2. Patients in this group had severe osteitis fibrosa:
The number of active bone cells, osteoclasts, and osteoblasts
was greatly increased. Osteoid volume was above normal in all
patients, and the mean osteoid thickness was elevated in
patients 6 and 8. The extent of the mineralization front,
measured on toluidine blue stained sections, was in the normal
range in all subjects (Table 2). Nevertheless, the uptake of the
Fig. 1. Al localization in bone tissue of patient
1. A Semithin section stained by toluidine
blue. Abbreviations are: o, osteoid tissue;
BM, mineralized bone matrix. (x316) B Al
distribution shown by ion microscopy in the
same region as in panel A. Al (white arrows)
is concentrated between osteoid and the
mineralized bone matrix. (x 316) C and D
Ultrastructure of the osteoid tissue near the
mineralized matrix. Large hexagonal
structures are seen, emitting x-rays
characteristic for P and Al (inset). (unstained)
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fluorescent tetracycline label was patchy and diffuse, and in the
two double-labelled patients, 6 and 7, the fluorescent zones
were often confluent, so that the measurement of the mineral-
ization rate was not possible. Bone Al was high in all patients.
In patient 6, Al was seen by ion microscopy on cement lines,
and between osteoid and mineralized matrix. The comparison
of serial sections examined by this technique or stained by
toluidine blue, showed that in some regions Al was concentrat-
ed on an active mineralizing osteoid layer. In the samples of
patients 7 and 8, no Al localization could be detected by ion
microscopy. Figure 2 shows the EM aspect of the mineraliza-
tion front of patient 6; similar observations were made in the
other two subjects. The osteoid seam was composed of several
layers of organic matrix, which contained electron dense mate-
rial unobserved near the osteoblasts. At some distance from
these cells, dense clusters, 50 to 1,000 A in diameter, were seen
on collagen fibrils. In these clusters, x-ray microprobe revealed
clear peaks for Al, but not for calcium (Fig. 2B, inset). Deeper
in the osteoid tissue, these Al-deposits were seen next to
amorphous calcium-containing material, and they also occurred
in contact with some poorly defined hydroxyapatite needles
(Fig. 2A, inset). The Al-deposits were bigger and more clearly
delineated inside the incompletely mineralized matrix.
In all patients of this group, the osteoblasts appeared very
active with numerous cytoplasmic processes. The Golgi com-
plex and the endoplasmic reticulum were well developed and
free ribosomes were present in large number. Numerous mito-
chondria were seen (Fig. 3): Most of them contained small
granules of calcium phosphate (Fig. 3A, thin arrows, inset), but
some mitochondria were loaded with dense amorphous material
(Fig. 3, thick arrow), emitting x-rays characteristic for Al and
phosphorus (Fig. 3, A and B, insets) and not for calcium. These
Al deposits were seen in the osteoblasts of all three patients
with osteitis fibrosa. They were much bigger than the calcium
granules, measuring about 1,500 to 2,000 A. In some cells, the
membranes of the two types of mitochondria tended to fuse
together (Fig. 3, B and C). In the Al-containing mitochondria
the cristae were often disoriented and disintegrated, and the
matrix had a patchy appearance. Similar mitochondria were
also seen in the preosteoblasts and the young osteocytes. The
osteocytic lacuna was large with an irregular border, and the
lacunar cavity contained collagen fibrils and flocculent materi-
n
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al. The aspect of the osteoclasts suggested decreased resorptive
activity. Some of them were in contact with the osteoid tissue.
In those in contact with the calcified matrix, the brush border
was formed of a few cytoplasmic processes, which contained
poor electron-dense material. No Al was detectable in this
material. The mitochondria appeared relatively reduced in
number and did not contain Al.
Discussion
These results confirm earlier observations that, in Al-intoxi-
cated hemodialyzed patients, severe osteomalacia is only ob-
served in the absence of osteitis fibrosa [2, 3]. Moreover, the
ultrastructural analysis of the bone tissue of the patients report-
ed in this study suggests that osteoblasts may be target cells for
the toxic action of Al on bone.
Fig. 2. Osteoid border of patient 6. On the top
of the image is the mineralization front, on the
bottom the cytoplasm of an osteoblast.
Several layers of collagen fibrils are observed,
which contain different electron-dense
deposits. All these deposits emit x-rays
characteristic for Al, (insets A and B) and
some of them completely mask the cross-
section of the fibrils. The x-ray microprobe of
the deposits next to the osteoblasts do not
reveal clear peaks for calcium (B), whereas
these peaks appear clearly in the deposits next
to the mineralization front (A).
The subjects were selected because they had elevated plasma
Al concentrations. Bone Al content was not strikingly elevated
in all patients. Patient 4 developed osteomalacia with bone Al
content lower than the bone content of patients with osteitis
fibrosa. A similar observation has been reported by Hodsman et
al [3]. Regarding the localization of Al within the bone tissue,
ion microscopy showed Al concentration at the mineralizing
layer of osteoid in all group 1 osteomalacic patients. Among the
patients with osteitis fibrosa (group 2), only in patient 6 could Al
be localized by this technique; in the other two Al was detected
by ion microscopy but was localized only by the ultrastructural
analysis, although their bone Al content was not different from
the bone Al content of group 1 patients. This difference between
osteomalacic and fibrotic bone confirms our earlier findings [2]
and has recently been observed by Ott et al [121.
Fig. 3. Cytoplasm of an osteoblast of patient
6, containing well developed endoplasmic
reticulum. Small, dense granules are present
in the mitochondria, emitting x-rays for Ca
and P (thin arrows, A inset) or large deposits
containing Al, P, and Os (large arrows, A and
B insets).
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The reason for the absence of osteitis fibrosa in the osteoma-
lacic patients and for their low iPTH plasma level are uncertain.
It has been suggested that Al may have a direct toxic action on
parathyroid glands, since low calcium dialysate does not in-
crease the plasma iPTH of osteomalacic patients, in contrast to
what occurs in control patients with osteitis fibrosa [13, 14]. In
rats, parenteral administration of Al decreases the plasma N-
terminal iPTH concentration [8]. Furthermore, parathyroid
glands preferentially accumulate Al [15] and, in vitro, Al
inhibits the secretion of iPTH from parathyroid cells, although
at much higher concentrations than those measured in human
plasma [16, 17]. This relative PTH deficiency observed in
dialysis osteomalacia may contribute to the low cellular activity
observed in the bone tissue but cannot be at the origin of the
mineralization defect. As a matter of fact, in patients with
hypoparathyroidism, osteomalacia does not occur, except in
the presence of longstanding hypocalcemia [18]. This is not the
case in Al-intoxicated patients, who easily develop hypercalce-
mia. In addition, experimental studies in rats [19] and dogs [20]
have shown that lack of PTH does not induce osteomalacic
lesions.
At the present time, the mechanism by which bone mineral-
ization normally occurs is not fully understood. It is clear that
the activity of the osteoblasts plays an important role. These
cells synthetize the calcifiable matrix as well as a number of
specific factors which inhibit or promote mineralization [21]. In
embryonic bone, the initial site of apatite nucleation is localized
in structures which derive directly from the cells, that is,
vesicles or osteoblast extrusions [22]. In mature bone, most
mineral deposition occurs on collagen fibrils [22] and pre-
existing crystals [23], although the presence of vesicles near the
osteoblasts has been reported [23]. Therefore, intact osteoblast
activity is essential not only for matrix deposition but also for
matrix mineralization.
In this study, the number and the activity of the osteoblasts
were reduced in group 1 and increased in group 2. This
difference can be ascribed to the differences in the severity of
secondary hyperparathyroidism between the two groups, since
it has been shown that in uremic patients with severe osteitis
fibrosa the number of the osteoblasts and the bone apposition
rate are increased [24, 251.
In group 2 patients, the osteoblasts contained numerous
ribosomes, and well developed endoplasmic reticulum, indicat-
ing active protein synthesis. These cells also contained small
calcium granules and large Al deposits in their mitochondria,
whereas no Al deposits were observed in the osteoblasts of a
child with hereditary hypophosphatemic rickets and a nondia-
lyzed adult with chronic renal failure (unpublished results). It is
well known that mitochondria have a high affinity for Ca2. In
the cells of mineralizing tissues mitochondrial storage and
'U-eç •p% -;; a4$
802 Plachot et a!
release of Ca2 is closely related to extracellular mineral
deposition [26—281. Therefore, the retention of Al by the
mitochondria of the osteoblasts suggests that Al may in some
way interfere with the calcium fluxes, thus influencing the
normal mineral deposition. Indeed, in group 2 patients, al-
though the extent of the mineralization front was in the normal
range, the tetracycline uptake was patchy and diffuse, indicat-
ing that the mineralization was not completely normal. In
addition, the presence of abnormal calcium deposits in the
osteoid tissue, next to small and irregular Al containing clusters
suggests a possible direct action of Al on the deposition or the
growth of the hydroxyapatite crystals. This hypothesis is sup-
ported by recent in vitro data, showing that Al, at concentra-
tions similar to those measured in the serum from intoxicated
patients, inhibits both calcium uptake by a calcifiable matrix
and crystal formation from a metastable solution of calcium
phosphate, when incubated in the presence of citrate [291. It is
noteworthy that citrate is present in bone at high concentrations
and that its rate of production is increased by PTH [301. Further
studies are in progress to investigate the composition of the Al
deposits and to see whether Al is incorporated into the hy-
droxyapatite crystal, since natural Al-rich apatites have been
described [31], and synthetic apatites may contain more than 25
atomic percent of Al [32].
In the osteomalacic patients, no active osteoblasts were
observed. Since active bone cells are needed for osteoid
deposition, this histological aspect may represent the endstage
of the Al intoxication in the skeleton, and the large regular
structures in which Al is concentrated may be the result of local
Al processing after the activity of the osteoblasts has ceased.
However, in the absence of cellular control, some passive Al
diffusion cannot be excluded.
These data, although obtained on isolated patients, support
the hypothesis that Al accumulates in bone before the develop-
ment of the mineralization defect [7] and that osteitis fibrosa
may precede osteomalacia [31. It can reasonably be assumed
that secondary hyperparathyroidism, by increasing the number
of active bone cells, stimulates the uptake of Al by the
osteoblasts and its release into the organic matrix. Indeed, in
rats, the administration of PTH increases the bone Al concen-
tration [33]. With regard to the development of the osteomalacic
lesions, the presence of Al within the mitochondria of the
osteoblast may be one of the factors inducing the mineralization
defect. Such a direct action of Al on bone cells has been
observed in vitro. At low concentrations (1.5 x 10—6 M) Al
stimulates bone phosphatase activities, whereas these activities
are reduced at higher concentrations (6 x 10—6 M) [34]. Other
interferences of Al with enzymatic systems have been reported:
Al influences the F -induced activation of adenylate cyclase
[35], inhibits yeast and brain hexokinase in ATP preparations
[361, and blocks the activity of the calcium-calmodulin-depen-
dent phosphodiesterase [37]. But, during the course of intoxica-
tion, Al may also act indirectly on bone, through its toxic action
on the parathyroid glands [13, 14, 16, 17], the gradual decrease
of the iPTH plasma concentration leading to a decrease of the
bone cell activity. It is possible that pure dialysis osteomalacia,
which associates defective matrix mineralization and poor
cellular activity, only develops when Al has exerted its toxic
action both on osteoblasts and on parathyroid glands.
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